Key result
Cilostazol significantly decreased soluble adhesion molecule levels in patients with diabetes.
Why the study?
Does cilostazol reduce soluble adhesion molecules and platelet-derived microparticles in patients with non-insulin dependent diabetes mellitus?
Population
Patients with non-insulin dependent diabetes mellitus (NIDDM)
Comparison
Cilostazol vs Control subjects and pre-treatment baseline
Design
Cohort
Authors
Loading...
Cilostazol may mitigate endothelial activation in diabetes; supports prior observations but remains hypothesis-generating pending RCTs.
RCT
null
null
No
Does cilostazol reduce soluble adhesion molecules and platelet-derived microparticles in patients with non-insulin dependent diabetes mellitus?
Effect estimate: null (95% CI null)
p-value: p=null
Cilostazol significantly reduces levels of platelet-derived microparticles, activated platelets, and soluble adhesion molecules in patients with NIDDM, suggesting potential to inhibit vascular damage.
Nomura et al. (1998) conducted an RCT in Diabetes. Cilostazol vs. null was evaluated on Soluble adhesion molecules and platelet-derived microparticles levels (null, 95% CI null, p=null). Cilostazol significantly decreased soluble adhesion molecule levels in patients with diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: